AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Cybin Inc (CYBN) reported Q2 2026 earnings with cash-based operating expenses of $28.5mln, up from $18.2mln YoY. Net loss was $33.7mln, compared to $41.9mln last year. The company has completed enrollment for its Phase 2 CYB004 study and strengthened its capital position with a $175mln financing. CYB003 has been granted breakthrough therapy designation for major depressive disorder.

Daily stocks & crypto headlines, free to your inbox
Comments
No comments yet